PE20181376A1 - Analogos del egf(a) con sustituyentes de acidos grasos - Google Patents
Analogos del egf(a) con sustituyentes de acidos grasosInfo
- Publication number
- PE20181376A1 PE20181376A1 PE2018001257A PE2018001257A PE20181376A1 PE 20181376 A1 PE20181376 A1 PE 20181376A1 PE 2018001257 A PE2018001257 A PE 2018001257A PE 2018001257 A PE2018001257 A PE 2018001257A PE 20181376 A1 PE20181376 A1 PE 20181376A1
- Authority
- PE
- Peru
- Prior art keywords
- egf
- fatty acid
- bond
- analogs
- yglu
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- -1 methylsulfonylcarbamoylamino residue Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a un derivado de EGF(A) que comprende un analogo peptidico de EGF(A) del dominio EGF(A) de LDL-R definido por la SEC No. ID 1, que comprende 301 Leu y un sustituyente que comprende al menos un grupo de acido graso, como, por ejemplo, acido carboxilico, acido sulfonico, resto tetrazol, resto metilsulfonilcarbamoilamino, entre otros. Este sustituyente tiene la formula I, en donde Z1 se selecciona de: HOOC-(CH2)n-CO- , tetrazolil-(CH2)n-CO- , entre otros; Z2 es -NH-SO2-(CH3)3-CO- , entre otros; Z3 es yGlu, Glu o un enlace; Z4-Z5-Z6-Z7-Z8-Z9 se seleccionan de Glu, yGlu, Gly, Ser, Ala, Thr, Ado, Aeep, Aeeep, TtdSuc y un enlace; Z10 se selecciona de -NH-CH2-(C6H4)-CH2 y un enlace. Estos compuestos son utiles para el tratamiento de la hiperlipidemia, dislipidemia y enfermedad cardiovascular.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016070791 | 2016-01-13 | ||
| CN2016076580 | 2016-03-17 | ||
| EP16195965 | 2016-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181376A1 true PE20181376A1 (es) | 2018-09-05 |
Family
ID=57868232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001257A PE20181376A1 (es) | 2016-01-13 | 2017-01-13 | Analogos del egf(a) con sustituyentes de acidos grasos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10822385B2 (es) |
| EP (1) | EP3402811B1 (es) |
| JP (2) | JP6797926B2 (es) |
| KR (1) | KR102417487B1 (es) |
| CN (1) | CN108473550B (es) |
| AU (1) | AU2017207862B2 (es) |
| BR (1) | BR112018013820A2 (es) |
| CA (1) | CA3010756A1 (es) |
| CL (1) | CL2018001868A1 (es) |
| CO (1) | CO2018007440A2 (es) |
| DK (1) | DK3402811T3 (es) |
| ES (1) | ES2916998T3 (es) |
| HR (1) | HRP20220720T1 (es) |
| HU (1) | HUE058647T2 (es) |
| IL (1) | IL260043A (es) |
| LT (1) | LT3402811T (es) |
| MX (1) | MX2018008681A (es) |
| MY (1) | MY195199A (es) |
| PE (1) | PE20181376A1 (es) |
| PH (1) | PH12018501502A1 (es) |
| PL (1) | PL3402811T3 (es) |
| RS (1) | RS63298B1 (es) |
| RU (1) | RU2747877C2 (es) |
| SA (1) | SA518391996B1 (es) |
| SI (1) | SI3402811T1 (es) |
| WO (1) | WO2017121850A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049813T2 (hu) | 2016-01-13 | 2020-10-28 | Gruenenthal Gmbh | 3-((hetero-)aril)-alkil-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán származékok |
| DK3402811T3 (da) | 2016-01-13 | 2022-06-13 | Novo Nordisk As | Egf(a)-analoger med fedtsyresubstituenter |
| CA3011182A1 (en) | 2016-01-13 | 2017-07-20 | Grunenthal Gmbh | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| EA034904B1 (ru) | 2016-01-13 | 2020-04-03 | Грюненталь Гмбх | Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро-[4.5]-декана |
| WO2017121647A1 (en) | 2016-01-13 | 2017-07-20 | Grünenthal GmbH | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
| CA3068956A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Bifunctional compounds |
| MA49617A (fr) * | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
| WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID |
| AR116605A1 (es) | 2018-10-05 | 2021-05-26 | Novo Nordisk As | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) |
| CA3131997A1 (en) | 2019-03-22 | 2020-10-01 | 3M Innovative Properties Company | Fall-protection system with monitoring system |
| CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
| US20220323544A1 (en) | 2019-08-07 | 2022-10-13 | Novo Nordisk A/S | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| IL291893A (en) | 2019-11-07 | 2022-06-01 | Novo Nordisk As | Solid preparations comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909823A2 (en) | 2005-07-29 | 2008-04-16 | Amprotein Corporation | Chimeric therapeutic agents |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| MX2010011499A (es) | 2008-04-23 | 2010-11-12 | Amgen Inc | Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos. |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| JPWO2012017774A1 (ja) * | 2010-08-02 | 2013-10-03 | 日本電気株式会社 | 偏光子及び発光装置 |
| CN102153652A (zh) | 2010-12-10 | 2011-08-17 | 浙江大学 | 一种融合蛋白的表达方法及用途 |
| WO2012110422A1 (en) | 2011-02-15 | 2012-08-23 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| JP2014519848A (ja) * | 2011-06-20 | 2014-08-21 | ジェネンテック， インコーポレイテッド | Ｐｃｓｋ９結合ポリペプチドと使用方法 |
| TWI596110B (zh) * | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| US20140357838A1 (en) * | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
| CN112142855A (zh) | 2012-05-18 | 2020-12-29 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| AR092076A1 (es) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
| CN104736558A (zh) | 2012-09-07 | 2015-06-24 | 赛诺菲 | 用于治疗代谢综合征的融合蛋白 |
| AU2014255608B2 (en) * | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
| SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
| CA2935285A1 (en) | 2014-02-21 | 2015-08-27 | Medimmune, Llc | Anti-pcsk9-glp-1 fusions and methods for use |
| CN106536547A (zh) * | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| CA2979617C (en) * | 2015-03-19 | 2024-01-02 | Institut De Cardiologie De Montreal | Grp94 derived polypeptides for inhibiting pcsk9 and methods of use |
| CN105367884A (zh) | 2015-11-02 | 2016-03-02 | 陈薇 | 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法 |
| DK3402811T3 (da) | 2016-01-13 | 2022-06-13 | Novo Nordisk As | Egf(a)-analoger med fedtsyresubstituenter |
| MA49617A (fr) | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
| CA3068956A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Bifunctional compounds |
-
2017
- 2017-01-13 DK DK17701078.2T patent/DK3402811T3/da active
- 2017-01-13 HR HRP20220720TT patent/HRP20220720T1/hr unknown
- 2017-01-13 JP JP2018536444A patent/JP6797926B2/ja active Active
- 2017-01-13 HU HUE17701078A patent/HUE058647T2/hu unknown
- 2017-01-13 PL PL17701078T patent/PL3402811T3/pl unknown
- 2017-01-13 EP EP17701078.2A patent/EP3402811B1/en active Active
- 2017-01-13 CN CN201780006783.6A patent/CN108473550B/zh active Active
- 2017-01-13 BR BR112018013820-7A patent/BR112018013820A2/pt not_active Application Discontinuation
- 2017-01-13 KR KR1020187022105A patent/KR102417487B1/ko active IP Right Grant
- 2017-01-13 AU AU2017207862A patent/AU2017207862B2/en not_active Ceased
- 2017-01-13 PE PE2018001257A patent/PE20181376A1/es unknown
- 2017-01-13 CA CA3010756A patent/CA3010756A1/en not_active Withdrawn
- 2017-01-13 US US16/069,932 patent/US10822385B2/en active Active
- 2017-01-13 ES ES17701078T patent/ES2916998T3/es active Active
- 2017-01-13 MY MYPI2018702319A patent/MY195199A/en unknown
- 2017-01-13 LT LTEPPCT/EP2017/050668T patent/LT3402811T/lt unknown
- 2017-01-13 RU RU2018127882A patent/RU2747877C2/ru active
- 2017-01-13 SI SI201731149T patent/SI3402811T1/sl unknown
- 2017-01-13 RS RS20220538A patent/RS63298B1/sr unknown
- 2017-01-13 MX MX2018008681A patent/MX2018008681A/es unknown
- 2017-01-13 WO PCT/EP2017/050668 patent/WO2017121850A1/en active Application Filing
-
2018
- 2018-06-14 IL IL260043A patent/IL260043A/en unknown
- 2018-07-09 CL CL2018001868A patent/CL2018001868A1/es unknown
- 2018-07-10 SA SA518391996A patent/SA518391996B1/ar unknown
- 2018-07-12 PH PH12018501502A patent/PH12018501502A1/en unknown
- 2018-07-16 CO CONC2018/0007440A patent/CO2018007440A2/es unknown
-
2020
- 2020-09-17 US US17/024,264 patent/US20200407409A1/en not_active Abandoned
- 2020-11-17 JP JP2020190846A patent/JP2021035989A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181376A1 (es) | Analogos del egf(a) con sustituyentes de acidos grasos | |
| CU24643B1 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| AR115131A1 (es) | Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) | |
| CL2020002224A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil péptido | |
| CU20190069A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) | |
| UY37169A (es) | Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| PE20220488A1 (es) | Variantes del cnp y sus conjugados | |
| CU20190067A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr) | |
| MY195933A (en) | Method for Purification of Animal or Vegetable Fats | |
| MX2020008265A (es) | Derivados farmaceuticos del anillo heterobiciclico 6,5. | |
| CO2022001316A2 (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
| AR069437A1 (es) | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| EA201992226A1 (ru) | Агонисты npra, композиции и их использование | |
| PE20200720A1 (es) | Compuestos bifuncionales | |
| CR20180560A (es) | Ésteres de oxaboral y sus usos | |
| BR112019008453A2 (pt) | composições de polímero com plastificante de pbsa | |
| EA201792640A1 (ru) | Устойчивые к действию протеазы липидированные аналоги glp-1 | |
| PH12020550947A1 (en) | Polymorphs | |
| PE20181355A1 (es) | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 | |
| BR112021026061A2 (pt) | Método para o tratamento de uma composição que compreende vanilina natural | |
| CR20110305A (es) | Péptidos antagonistas de crhr2 y usos de estos |